|
Next's manufacturer in Asia is PhytoMedical Research Inc. (PRI), an international joint
venture company in Beijing. PRI's Chinese partner, CNC, has been responsible for
regulating the collection and re-distribution of herbal materials throughout China for
over 40 years and is an owner or partner in more than 40 herbal medicines manufacturing
companies in China. This provides Next with optimal raw material sourcing and extensive
production capacity in certified GMP manufacturing facilities. Through PRI's established
nationwide network of herb cultivators, Next's botanical raw materials are obtained
directly from certified "Green" agricultural bases, which means that the Provincial EPA
has tested and approved the water, soil, and air quality as well as the product purity of
each certified "Green" grower.
|
Manufacturing protocols are thoroughly researched and
standardized under Next's supervision in both the lab and GMP facilities in cooperation
with the PhD researchers at PRI. Each commercial production batch is produced under
PRI's supervision according to SOP's developed in Next's quality control research and
development program. Through PRI, a network of contacts throughout China has been
established with academic and research institutes with proven expertise in all phases of
botanical R&D, from pre-clinical safety and efficacy studies to development of
state-of-the-art quality control programs. These relationships involve the China
Academy of Medicine, China Academy of Traditional Chinese Medicine, Institute for
Medicinal Plant Development, the State Drug Administration, as well as leaders in other
key institutes and government agencies.
|
